Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04363801 · ClinicalTrials.gov registry record · Phase 2
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
A Phase 2 study, sponsored by Leap Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 247
- Enrollment target
NCT04363801 is a Phase 2 study that was terminated before completion, run by Leap Therapeutics. The registered enrollment target is 247 participants.
The verdict
NCT04363801, a Phase 2 study, was terminated before completion, sponsored by Leap Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 247 participants
- Enrollment target
Study Summary
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
- DRUG DKN-01 300mg
- DRUG DKN-01 600mg
- DRUG DKN-01 400mg
- DRUG Tislelizumab 200mg
- DRUG Tislelizumab 400mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04363801
The ClinicalTrials.gov registry entry for NCT04363801 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Leap Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which DKN-01 300mg is the first listed.
NCT04363801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04363801 about?
NCT04363801 is a clinical study titled "A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer". A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
What is the current status of trial NCT04363801?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 247 participants. The study started on 2020-07-29. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT04363801?
The interventions under investigation include: DKN-01 300mg (DRUG), DKN-01 600mg (DRUG), DKN-01 400mg (DRUG), Tislelizumab 200mg (DRUG), Tislelizumab 400mg (DRUG).
Who is sponsoring clinical trial NCT04363801?
This trial is sponsored by Leap Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.